¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"group III fiber"¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
À̰ÍÀ» ¿øÇϼ̽À´Ï±î?
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 7
  • ¿µ¹®
    ÇѱÛ
  • myelinated fiber
    ¸»ÀÌÁý½Å°æ¼¶À¯, À¯¼ö½Å°æ¼¶À¯
  • myelinated nerve fiber
    ¸»ÀÌÁý½Å°æ¼¶À¯, À¯¼ö½Å°æ¼¶À¯
  • mantle fiber
    ¿ÜÅõ¼¶À¯
  • medullated fiber
    ¸»ÀÌÁý½Å°æ¼¶À¯, À¯¼ö½Å°æ¼¶À¯
  • medullated nerve fiber
    ¸»ÀÌÁý½Å°æ¼¶À¯, À¯¼ö½Å°æ¼¶À¯
  • meridional fiber
    ³¯ÁÙ¼¶À¯
  • nerve fiber
    ½Å°æ¼¶À¯
  • neuroglial fiber
    ½Å°æ¾Æ±³¼¶À¯, ½Å°æ±³¼¶À¯
  • nonmyelinated fiber
    ¹Î¸»ÀÌÁý½Å°æ¼¶À¯, ¹«¼ö½Å°æ¼¶À¯
  • nonmyelinated nerve fiber
    ¹Î¸»ÀÌÁý½Å°æ¼¶À¯, ¹«¼ö½Å°æ¼¶À¯
  • nuclear bag fiber
    ÇÙÁָӴϼ¶À¯, ÇÙÁָӴϱÙ(À°)¼¼Æ÷
  • nuclear chain fiber
    Çٻ罽¼¶À¯, Çٻ罽±Ù(À°)¼¼Æ÷
  • odontogenic fiber
    Ä¡¾ÆÇü¼º¼¶À¯
  • oblique fiber
    ºø¼¶À¯
  • pilomotor fiber
    Åп¼¶À¯
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 7
  • ¿µ¹®
    ÇѱÛ
  • fiber
    ¼¶À¯
  • fusimotor fiber
    ±ÙÀ°¹æÃß¼¶À¯
  • gamma fiber
    °¨¸¶½Å°æ¼¶À¯
  • gingival fiber
    ÀÕ¸ö¼¶À¯
  • glass fiber
    À¯¸®¼¶À¯
  • impulse-conducting fiber
    (¢¡Purkinje fiber) ½ÉÀåÀüµµ±ÙÀ°¼¶À¯, Ǫ¸£Å°´Ï¿¡¼¶À¯
  • intercrural fiber
    ´Ù¸®»çÀ̼¶À¯
  • intrafusal muscle fiber
    ¹æÃß¼Ó±ÙÀ°¼¼Æ÷
  • light fiber
    ¹àÀº±ÙÀ°¼¶À¯, ¹àÀº±ÙÀ°¼¼Æ÷
  • longitudinal fiber
    ¼¼·Î¼¶À¯
  • mantle fiber
    ¿ÜÅõ¼¶À¯
  • medullated fiber
    (¢¡myelinated nerve fiber) ¸»ÀÌÁý½Å°æ¼¶À¯
  • medullated nerve fiber
    (¢¡myelinated nerve fiber) ¸»ÀÌÁý½Å°æ¼¶À¯
  • meridional fiber
    ³¯ÁÙ¼¶À¯
  • mossy fiber
    À̳¢¼¶À¯
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 7
  • ¿µ¹®
    ÇѱÛ
  • group antigen
    ±ºÇ׿ø(ÏØù÷ê«).
  • group audiometry
    Áý´Üû·Â°Ë»ç(¹ý)
  • group conformity rating =GCR
    Áý´ÜÇÕÄ¡ µî±ÞºÐ·ù(ÊṴ̬̀ËÄË»ËÓËÈ).
  • group discussion
    Áý´ÜÅäÀÇ(̤ËÀ̬Ëö).
  • group displacement law
    Áý´Üº¯À§¹ýÄ¢(ÊÙËÒ ËôËÑ̬).
  • group dynamics
    Áý´Ü¿ªÇÐ(ÊÙËç ).
  • group file
    ±×·ì È­ÀÏ
  • group hearing aid
    Áý´Üº¸Ã»±â
  • group hospital
    º´¿øÁ¶ÇÕ(ËÓËô̡̰).
  • group incompatibility
    Ç÷¾×±ººÎÀûÇÕ(úìäûÏØ ÝÕîêùê).
  • group medicine
    Áý´Ü<Çùµ¿>Áø·á.
  • group of isogenous chondrocyte
    ¿¬°ñ¼¼Æ÷¹«¸®
  • group of muscles
    ±ÙÀ°¹«¸®, ±Ù__ÐÉÏØ).
  • group of muscles
    ±ÙÀ°¹«¸®, ±Ù±º(ÐÉÏØ).
  • group practice
    Áý´Ü°³¾÷(̤ËÀ˧ ).
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 7
  • ¿µ¹®
    ÇѱÛ
  • incompatibility group, plasmid
    ÇÃ¶ó½º¹Ìµå ºñÀûÇÕ±º
  • indeterminate group
    ¹ÌÁ¤Çü±º(ËÑËøÌ´Ë´).
  • indeterminate group
    ¹ÌÁ¤Çü±º(Ú±ïÒúþÏØ).
  • labile methyl group
    ºÒ¾ÈÁ¤¸ÞÆ¿±â.
  • linkage group
    ¿¬¼â±º(ææáðÏØ).
  • marathon group
    ¸¶¶óÅæÁý´Ü
  • methyl group
    ¸ÞÆ¿±â.
  • minority group
    ¼Ò¼ö±×·ì.
  • nonionic polar group
    ºñÀ̿±ؼº±â.
  • open group
    °ø°³Áý´Ü(˭˧̤ËÀ), °³¹æÁý´Ü (˧ËÑ̤ËÀ).
  • osmophore group
    ¹ßÇâ´Ü(Û¡úÅÓ¥).
  • p1 blood group
  • permutation group
    ġȯ?öÇüµÏØ).
  • permutation group
    ġȯ±º(̷̬˴).
  • permutation group
    ġȯ±º(öÇüµÏØ).
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 7
  • ¿µ¹®
    ÇѱÛ
  • t-Boc group
    t-Boc ±â (Ðñ)
  • thiol group
    ŸÀ̿ñâ(Ðñ)
  • tosyl group
    Åä½Ç±â(Ðñ)
  • trityl group
    Æ®¸®Æ¿±â(Ðñ)
  • Vitamin B group
    ºñŸ¹Î B ±º(ÏØ)
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 7
HFD hemorrhagic fever of deer; high-fiber diet; high forceps delivery; hospital field director; human fa...
LFD lactose-free diet; large for date [fetus]; late fetal death; lateral facial dysplasia; least fatal d...
LGF lateral giant fiber
MFCV muscle fiber conduction velocity
NFL nerve fiber layer; neurofilament protein, light polypeptide
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 7
group 3 group 1
Group 4 group
Group A group 1
group B group A
Group D group
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 11 ÆäÀÌÁö: 7
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
  • stretched fiber
    ½ÅÀåµÈ ¼¶À¯
  • substance P fiber
    P ¹°Áú ¼¶À¯
  • tendinous fiber
    °Ç ¼¶À¯
  • uncinate fiber
    °¥°í¸® ¼¶À¯
  • unmyelinated nerve fiber
    ¹«¼öÃÊ ½Å°æ ¼¶À¯, ¹«¼ö ½Å°æ ¼¶À¯
    ¼öÁú ¶Ç´Â ¼öÃʸ¦ °®Áö ¾Ê´Â ½Å°æ ¼¶À¯.
  • unmyelinated primary afferent fiber
    ÀÏÂ÷ ¹«¼ö ±¸½É¼º ¼¶À¯
  • ventral root afferent fiber
    ±¸½É¼º º¹Ãø±Ù ¼¶À¯
  • ventral root unmyelinated fiber
    º¹Ãø±Ù ¹«¼ö¼¶À¯
  • von Korff fiber
    ÆùÄÚ¸£ÇÁ ¼¶À¯, von Korff¼¶À¯
  • wavy fiber
    ÆÄ»ó ¼¶À¯
  • white muscle fiber
    ¹é»ö ±Ù ¼¶À¯
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 7
group agglutinin An immune agglutinin specific for a group antigen.
Synonym: cross-reacting agglutinin.
(05 Mar 2000)
group antigens Antigen's that are shared by related genera of microorganisms.
(05 Mar 2000)
group A streptococcal necrotizing fasciitis A complication of infection with GAS (group A streptococci) in which the bacteria attacks and destroys muscle tissue. According to the CDC, 5-10% of people with severe GAS infection develop necrotizing fasciitis. Though the infection can be treated with antibiotics, the fatality rate is close to 30%. This complication often develops as a wound infection after surgery or injury.
(05 Mar 2000)
group A streptococci A common bacteria that is the cause of strep throat, scarlet fever, impetigo, cellulitis-erysipelas, rheumatic fever, acute glomerular nephritis, endocarditis, and group A streptococcal necrotizing fasciitis. The prototype is Streptococcus pyogenes.
(05 Mar 2000)
group B streptococci A leading cause of a form of neonatal sepsis that has a 10-20% mortality rate and leaves a large number of survivors with brain damage. Also a leading cause of meningitis.
(05 Mar 2000)
group dynamics A term used to represent the study of underlying features of group behaviour, e.g., motives, attitudes; it is concerned with group change rather than with static characteristics.
(05 Mar 2000)
group homes Housing for groups of patients, children, or others who need or desire emotional or physical support. They are usually established as planned, single housekeeping units in residential dwellings that provide care and supervision for small groups of residents, who, although unrelated, live together as a family.
(12 Dec 1998)
group hospital A private hospital organised and controlled by a group of physicians and restricted to the reception and care of their own patients.
(05 Mar 2000)
group II mycobacteria Mycobacteria that produce a yellow pigment even when grown in the dark; when grown in the light, the pigment is orange. These organisms behave as do saprophytes in humans and are nonpathogenic to laboratory animals.
Synonym: scotochromogens.
(05 Mar 2000)
group immunity <immunology> Resistance of a group to a pathogen due to immunity of a large proportion of the group to that pathogen.
(09 Oct 1997)
group I mycobacteria Mycobacteria that produce a bright yellow colour when grown in the presence of light. Organisms placed in this group appear to belong to the species Mycobacterium kansasii.
Synonym: photochromogens.
(05 Mar 2000)
group IV mycobacteria Mycobacteria that grow rapidly and that do not produce pigment. Organisms placed in this group belong to such species as Mycobacterium ulcerans and M. Marinum.
(05 Mar 2000)
group practice Any group of three or more full-time physicians organised in a legally recognised entity for the provision of health care services, sharing space, equipment, personnel and records for both patient care and business management, and who have a predetermined arrangement for the distribution of income.
(12 Dec 1998)
group practice, dental Any group of three or more full-time dentists, organised in a legally recognised entity for the provision of dental care, sharing space, equipment, personnel and records for both patient care and business management, and who have a predetermined arrangement for the distribution of income.
(12 Dec 1998)
group practice, prepaid An organised group of three or more full-time physicians rendering services for a fixed prepayment.
(12 Dec 1998)
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
  • ¿µ¹®
    ÇѱÛ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 7
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 7
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 7
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 7
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 7
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 7
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 7
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 7
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 7
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 7
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 7
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 7
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 7
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 7
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
  • ¿µ¹®
    ÇѱÛ
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 7
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 7
ÅëÇÕ°Ë»ö ¿Ï·á